Alzheimer’s disease poses a burgeoning public health and fiscal threat to the U.S.  Beyond its impact on patients and their loved ones, Alzheimer’s significantly affects directions in long-term care and healthcare payment reform, and the future shape of the U.S. workforce. Alzheimer’s research is also a key area of current pharmaceutical industry investment; the speed at which new Alzheimer’s therapies enter the market will have a profound effect on patients, physicians, manufacturers, and long-term care providers. 

This 90-minute Avalere audio conference will discuss:

• Unique features of Alzheimer’s that impact spending across a wide range of federal agencies including the FDA, CMS, and NIH
• How long-term care reform and Alzheimer’s are integrally linked
• New Avalere analysis comparing FDA review times for Alzheimer’s, HIV/AIDS, and cancer therapies
• The FDA’s role in accelerating development and approval of new Alzheimer’s therapies

• Lauren Barnes, Director, Avalere Health
• Dan Perry, Executive Director, Alliance for Aging Research
• Janet Woodcock, MD, Deputy Commissioner and Chief Medical Officer, Food and Drug Administration

Registration Prices :
Avalere Client	$300
Commercial	$375
Government	$50
Non-profit	Special rates apply*

Cancellation Policy: To receive a refund, notice is required at least seven business days prior to the audio conference. With proper notice, fees are refunded minus a $40 service fee. No refunds are given for cancellations received with less than seven days notice. Avalere Health reserves the right to cancel or reschedule an audio conference due to unforeseen circumstances.